|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Retrospective analysis of extra-gastrointestinal stromal tumors显示文摘AIM:To investigate the clinicopathologic features of patients with extra-gastrointestinal stromal tumors(EGISTs)in South Korea.METHODS:A total of 51 patients with an EGIST were identified.The clinicopathologic features,including sex,age,location,tumor size,histology,mitotic rate,immunohistochemical features,genetic status and survival data,were analyzed.RESULTS:The median age was 55 years(range:29-80years),and male:female ratio was 1:1.04.The most common site was in the mesentery(n=15)followed by the retroperitoneum(n=13)and omentum(n=8).The median tumor size was 9.0 cm(range:2.6-30.0cm)and the median mitotic rate was 5.0/50HPF.(1/50-185/50).KIT was analyzed in 16,which revealed 10cases with wild-type KIT and 6 cases with an exon 11mutation.Among 51 patients,31 patients had undergone surgery,and 10 had unresectable disease and had taken palliative imatinib,which resulted in 22.7 mo of progression-free survival.Of the patients who had undergone surgery,18 did not take adjuvant imatinib,and 8 of these were categorized as'high risk'according to the risk criteria.However,the relapse-free survival was not different(P=0.157)between two groups.CONCLUSION:Because the biologic behaviors of GISTs differ according to the location of the tumor,a more stratified strategy is required for managing EGISTs including incorporation of molecular features. | Jun Ho Yi Byeong-Bae Park Jung Hun Kang In Gyu Hwang Dong Bok Shin Sun Jin Sym Hee Kyung Ahn Soon Il Lee Do Hyoung Lim Keon Woo Park Young-Woong Won Sung Hee Lim Se Hoon Park | 2015 | World Journal of Gastroenterology2015，21，6： | 9 |
| 2 | Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study显示文摘Background:Combination therapy with oxaliplatin,irinotecan,fluorouracil,and leucovorin(FOLFIRINOX)chemotherapy drastically improves survival of advanced pancreatic cancer patients.However,the efficacy of FOLFIRINOX as a second-line treatment after gemcitabine failure has not been tested prospectively.We investigated the feasibility and safety of attenuated FOLFIRINOX in patients with gemcitabine-refractory advanced pancreatic cancer.Methods:A multicenter phase II prospective open-label,single-arm study was conducted at 14 hospitals.Patients with histologically proven invasive ductal pancreatic adenocarcinoma,a measurable or evaluable lesion,Eastern Cooperative Oncology Group performance status 0 or 1,adequate organ function,and aged 19 years or older were eligible.Attenuated FOLFIRINOX consisted of oxaliplatin 65 mg/m2,irinotecan 135 mg/m2,and leucovorin 400 mg/m2 injected intravenously on day 1 and 5-fluorouracil 2000 mg/m2 continuously infused intravenously over 46 h on days 1-2,repeated every 2 weeks.The primary endpoint was progression-free survival from the initiation of FOLFIRINOX.Secondary endpoints were the objective response rate,disease control rate,overall survival,safety,and tolerability.We estimated overall survival and progression-free survival using the Kaplan-Meier methods.Results:We enrolled 39 patients from 14 institutions.The objective response rate was 10.3%,while the disease control rate was 64.1%.The 6-month and 1-year overall survival rates were 59.0%and 15.4%,respectively.Median progression-free survival and overall survival were 3.8 months(95%confidence interval[CI]1.5-6.0 months)and 8.5 months(95%CI 5.6-11.4 months),respectively.Grade 3 or 4 adverse events were neutropenia(41.0%),nausea(10.3%),anorexia(10.3%),anemia(7.7%),mucositis(7.7%),pneumonia/pleural effusion(5.1%),and fatigue(5.1%).One treatment-related death attributable to septic shock occurred.Conclusion:Attenuated FOLFIRINOX may be promising as a second-line therapy for gemcitabine-refractory pancre-atic cancer. | Jung Hoon Kim Sang-Cheol Lee Sung Yong Oh Seo-Young Song Namsu Lee Eun Mi Nam Soonil Lee In Gyu Hwang Hyo Rak Lee Kyu Taek Lee Sang-Byung Bae Han Jo Kim Joung Soon Jang Do Hyoung Lim Hyun Woo Lee Seok Yun Kang Jung Hun Kang | 2018 | Cancer Communications2018，38，1： | 2 |
| 3 | Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma显示文摘AIM: To assess the efficacy and safety of weekly docetaxel plus a fixed-dose rate(FDR) of gemcitabine in metastatic esophageal squamous cell carcinoma(SCC).METHODS: A multi-center, open-label, prospective phase Ⅱ study was designed.Thirty-three esophageal SCC patients with documented progression after fluoropyrimidine/platinum-based first-line chemotherapy were enrolled and treated with docetaxel 35 mg/m2 and gemcitabine 1000 mg/m2 iv at a FDR(10 mg/m2 per minute) on days 1 and 8.Treatment was repeatedevery twenty-one days until disease progression, unacceptable toxicity, or consent withdrawal.The primary endpoint was response rate(RR), and secondary endpoints were safety, progression-free survival(PFS) and overall survival(OS).RESULTS: Combination of weekly docetaxel and FDR gemcitabine was well tolerated: the most common treatment-related adverse events were anemia(97%), fatigue(64%) and neutropenia(55%).One patient with multiple lung and lymph node metastases died of respiratory failure after receiving four cycles of chemotherapy, and the possibility of drug-induced pneumonitis could not be completely excluded.Disease control(objective response plus stable disease) in the ITT population was achieved in 88% of patients, and the overall RR was 30%(95%CI: 15%-46%).The median PFS and OS were 4.0(95%CI: 3.4-4.6) and 8.8 mo(95%CI: 7.8-9.8 mo), respectively.CONCLUSION: A combination of weekly docetaxel and FDR gemcitabine showed promising antitumor activity and tolerability in previously treated, metastatic esophageal SCC. | Min-Young Lee Ki Sun Jung Hae Su Kim Ji Yun Lee Sung Hee Lim Moonjin Kim Hyun Ae Jung Sung Min Kim Jong Mu Sun Myung-Ju Ahn Jeeyun Lee Se Hoon Park Seong Yoon Yi In Gyu Hwang Sang-Cheol Lee Hee Kyung Ahn Do Hyoung Lim Soon Il Lee Keon Woo Park | 2015 | World Journal of Gastroenterology2015，21，14： | 2 |
| 4 | Liver Stiffness Measurement Using Acoustic Radiation Force Impulse (ARFI) Elastography and Effect of Necroinflammation显示文摘 | Ki Tae Yoon Sun Min Lim Jun Yong Park Do Young Kim Sang Hoon Ahn Kwang-Hyub Han Chae Yoon Chon Mong Cho Jun Woo Lee Seung Up Kim | 2012 | Digestive Diseases and Sciences2012，，6： | 1 |
| 5 | A New Suggestion for the Radiation Target Volume After a Subtotal Gastrectomy in Patients With Stomach Cancer显示文摘 | Heerim Nam Do Hoon Lim Sung Kim Won Ki Kang Tae Sung Sohn Jae Hyung Noh Yong Il Kim Chan Hyung Park Chul Keun Park Yong Chan Ahn Seung Jae Huh | 2008 | International Journal of Radiation Oncology Biology Physics2008，，2： | 1 |
| 6 | An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach显示文摘 | Sung Kim Do Hoon Lim Jeeyun Lee Won Ki Kang John S. MacDonald Chan Hyung Park Se Hoon Park Se-Hoon Lee Kihyun Kim Joon Oh Park Won Seog Kim Chul Won Jung Young Suk Park Young-Hyuck Im Tae Sung Sohn Jae Hyung Noh Jin Seok Heo Yong Il Kim Chul Keun Park Keu | 2005 | International Journal of Radiation Oncology Biology Physics2005，，5： | 1 |
| 7 | Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer显示文摘 | Hyo Song Kim Seong Yoon Yi Hyun Jung Jun Jeeyun Lee Se Hoon Park Jong Kyun Lee Kyu Taek Lee Kwang Hyuck Lee Dong Wook Choi Seong-Ho Choi Jin Seok Heo Young Suk Park Ho Yeong Lim Won Ki Kang Hee Chul Park Do Hoon Lim Joon Oh Park | 2010 | Anti-Cancer Drugs2010，，1： | 1 |
| 8 | An Observational Study Suggesting Clinical Benefit For Adjuvant postoprerative Chemoradiation In a Population of Over 500 Cases After gastric Resection with D2 Nodal Dissection for Adenocarcinoma of the Stomach显示文摘 | Sung Kinm Do Hoon Lim | 2005 | Int J Radiation Oncology Biol Phys2005，63，5： | 1 |
| 9 | A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma显示文摘 | Byeong-Bae Park Joon Oh Park Hyo Rak Lee Jeeyun Lee Dong Wook Choi Seong-Ho Choi Jin Seok Heo Jong Kyun Lee Kyu Taek Lee Do Hoon Lim Young Suk Park Ho-Yeong Lim Won Ki Kang Keunchil Park | 2007 | Cancer Chemotherapy and Pharmacology2007，，4： | 1 |
| 10 | Synergistic strengthening by load transfer mechanism and grain refinement of CNT/Al–Cu composites显示文摘 | Dong H. Nam Seung I. Cha Byung K. Lim Hoon M. Park Do S. Han Soon H. Hong | 2012 | Carbon2012，，7： | 1 |
| 11 | A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma显示文摘 | Byeong-Bae Park Joon Oh Park Hyo Rak Lee Jeeyun Lee Dong Wook Choi Seong-Ho Choi Jin Seok Heo Jong Kyun Lee Kyu Taek Lee Do Hoon Lim Young Suk Park Ho-Yeong Lim Won Ki Kang Keunchil Park | 2007 | Cancer Chemotherapy and Pharmacology2007，，4： | 1 |
| 12 | Radiation therapy for abdominal lymph node metastasis from hepatocellular carcinoma显示文摘 | Young Je Park Do Hoon Lim Seung Woon Paik Kwang Cheol Koh Joon Hyoek Lee Moon Seok Choi Byung Chul Yoo Hee Rim Nam Dong Ryul Oh Won Park Yong Chan Ahn Seung Jae Huh | 2006 | Journal of Gastroenterology2006，，11： | 1 |
| 13 | Potentially curative stereotactic body radiation therapy (SBRT) for single or oligometastasis to the lung显示文摘 | Dongryul Oh Yong Chan Ahn Jeong Min Seo Eun Hyuk Shin Hee Chul Park Do Hoon Lim Hongryull Pyo | 2012 | Acta Oncologica2012，，5： | 1 |
| 14 | Potentially curative stereotactic body radiation therapy (SBRT) for single or oligometastasis to the lung显示文摘 | Dongryul Oh Yong Chan Ahn Jeong Min Seo Eun Hyuk Shin Hee Chul Park Do Hoon Lim Hongryull Pyo | 2012 | Acta Oncologica2012，，5： | 1 |
| 15 | Liver Stiffness Measurement Using Acoustic Radiation Force Impulse (ARFI) Elastography and Effect of Necroinflammation显示文摘 | Ki Tae Yoon Sun Min Lim Jun Yong Park Do Young Kim Sang Hoon Ahn Kwang-Hyub Han Chae Yoon Chon Mong Cho Jun Woo Lee Seung Up Kim | 2012 | Digestive Diseases and Sciences2012，，6： | 1 |
| 16 | Clinical impact of combined transarterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: An external validation study显示文摘 | Jeong Il Yu Jae Won Park Hee Chul Park Sang Min Yoon Do Hoon Lim Joon Hyeok Lee Han Chu Lee Seon Woo Kim Jong Hoon Kim | 2015 | Radiotherapy and Oncology2015，，： | 1 |
| 17 | An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach显示文摘 | Sung Kim Do Hoon Lim Jeeyun Lee | 2005 | Int J Radiat Oncol Biol Phys2005，63，5： | 1 |
| 18 | Local radiotherapy for patients with unresectable hepatocellular carcinoma显示文摘 | Won Park Do Hoon Lim Seung Woon Paik Kwang Cheol Koh Moon Seok Choi Cheol Keun Park Byung Chul Yoo Jeong Eun Lee Min Kyu Kang Young Je Park Hee Rim Nam Yong Chan Ahn Seung Jae Huh | 2005 | International Journal of Radiation Oncology Biology Physics2005，，4： | 1 |
| 19 | Predictive factors of gastroduodenal toxicity in cirrhotic patients after three-dimensional conformal radiotherapy for hepatocellular carcinoma显示文摘 | Haeyoung Kim Do Hoon Lim Seung Woon Paik Byung Chul Yoo Kwang Gheol Koh Joon Hyoek Lee Moon Seok Choi Won Park Hee Chul Park Seung Jae Huh Doo Ho Choi Yong Chan Ahn | 2009 | Radiotherapy and Oncology2009，，2： | 1 |
| 20 | Clinical outcomes of radiation therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma显示文摘AIM:To evaluate the clinical outcomes of radiation therapy(RT)for early-stage gastric mucosa-associated lymphoid tissue lymphoma(MALToma).METHODS:The records of 64 patients treated between 1998 and 2011 were analyzed retrospectively.For Helicobacter pylori(H.pylori)-positive patients(n=31),chemotherapy or H.pylori eradication therapy was the initial treatment.In patients with failure after H.pylori eradication,RT was performed.For H.pylorinegative patients(n=33),chemotherapy or RT was the first-line treatment.The median RT dose was 36Gy.The target volume included the entire stomach andthe perigastric lymph node area.RESULTS:All of the patients completed RT without interruption and showed complete remission on endoscopic biopsy after treatment.Over a median follow-up period of 39 mo,the 5-year local control rate was 89%.Salvage therapy was successful in all relapsed patients.Secondary malignancies developed in three patients.The 5-year overall survival rate was 94%.No patient presented symptoms of moderate-to-severe treatmentrelated toxicities during or after RT.CONCLUSION:Radiotherapy results in favorable clinical outcomes in patients with early-stage gastric MALToma who experience failure of H.pylori eradication therapy and those who are H.pylori negative. | Sang-Won Kim Do Hoon Lim Yong Chan Ahn Won Seog Kim Seok Jin Kim Young Hyeh Ko Kyoung-Mee Kim | 2013 | World Journal of Gastroenterology2013，19，36： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员